Rat model of diabetic nephropathy
A rat model of diabetic nephropathy is disclosed. In another embodiment of the invention, a method of evaluating a test compound's effect of diabetic nephropathy is disclosed. In one embodiment, this method comprises the steps of (a) exposing the test compound to the rat of claim 1 , wherein the rat would develop progressive proteinuria and glomerulosclerosis leading to diabetic nephropathy in the absence of the test compound, and (b) comparing the rat's development of diabetic nephropathy with a control T2DN mimic rat that has not been exposed to the test compound.
1. A rat diabetes model, wherein the rat develops symptoms of type II diabetes and progressive diabetic nephropathy with nodule formation and wherein the rat is a T2DN rat comprising mitochondrial genome and loci on chromosomes 2 (D2Rat12), 11 (D11Rat93), 16 (D16Rat15), 19 (D19Rat59), and X (DXMit4 and DXMit42) from a Fawn Hooded rat into a GK rat, wherein the T2DN rat does not comprise GK alleles at markers D3Rat57, D11Mgh5, D12Rat22, D1Rat 291, D1Mit18, D1Mit34, D1Mgh12, and D1Rat85, and wherein the T2DN rat develops progressive proteinuria and glomerulosclerosis leading to diabetic nephropathy.
2. The rat of claim 1 , wherein the rat is of strain T2DN Mimic MCW .
3. The T2DN rat of claim 1 wherein the T2DN rat is further genetically altered by introducing additional genetic material.
4. The T2DN rat of claim 1 wherein the T2DN rat is further genetically altered by introducing genetic deletions.
5. A rat comprising mitochondrial genome and loci on chromosomes 2 (D2Rat12), 11 (D11Rat93), 16 (D16Rat15), 19 (D19Rat59), and X (DXMit4 and DXMit42) from a Fawn Hooded rat into a GK rat, wherein the rat does not comprise GK alleles at markers D3Rat57, D11Mgh5, D12Rat22, D1Rat291, D1Mit18, D1Mit34, D1Mgh12, and D1Rat85, and wherein the rat is obtained by breeding the T2DN rat of claim 1 with a second rat.
6. A rat comprising mitochondrial genome and loci on chromosomes 2 (D2Rat12), 11 (D11Rat93), 16 (D16Rat15), 19 (D19Rat59), and X (DXMit4 and DXMit42) from a Fawn Hooded rat into a GK rat, wherein the rat does not comprise GK alleles at markers D3Rat57, D11Mgh5, D12Rat22, D1Rat291, D1Mit18, D1Mit34, D1Mgh12, and D1Rat85, wherein the rat is obtained by breeding the rat of claim 4 with a second rat.
7. A cell line derived from the rat of claim 1 .
8. A cell line derived from the rat of claim 3 .
9. A method of evaluating the effect of a test compound on diabetes and diabetic nephropathy in a T2DN rat comprising the steps of:
(a) exposing the test compound to a T2DN rat comprising mitochondrial genome and loci on chromosomes 2 (D2Rat12), 11 (D11Rat93), 16 (D16Rat15), 19 (D19Rat59), and X (DXMit4 and DXMit42) from a Fawn Hooded rat into a GK rat, wherein the rat does not comprise GK alleles at markers D3Rat57, D11Mgh5, D12Rat22, D1Rat291, D1Mit18, D1Mit34, D1Mgh12, and D1Rat85, and wherein the T2DN rat would develop progressive proteinuria and glomerulosclerosis leading to diabetic nephropathy in the absence of the test compound, and
(b) comparing the development of diabetes and diabetic nephropathy in the treated T2DN rat with a control T2DN rat which has not been exposed to the test compound.
10. A method of evaluating the effect of a test compound on diabetes and diabetic nephropathy in a T2DN rat comprising the steps of:
(a) exposing the test compound to a genetically altered T2DN rat comprising mitochondrial genome and loci on chromosomes 2 (D2Rat12), 11 (D11Rat93), 16 (D16Rat15), 19 (D19Rat59), and X (DXMit4 and DXMit42) from a Fawn Hooded rat into a GK rat, wherein the rat does not comprise GK alleles at markers D3Rat57, D11Mgh5, D12Rat22, D1Rat291, D1Mit18, D1Mit34, D1Mgh12, and D1Rat85 and wherein the T2DN rat would develop progressive proteinuria and glomerulosclerosis leading to diabetic nephropathy in the absence of the test compound, and
(b) comparing the development of diabetes and diabetic nephropathy in the treated genetically altered T2DN rat with a control genetically altered T2DN rat which has not been exposed to the test compound, wherein the treated and the control rats comprise the same genetic modification.